Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
α-Syn aggregation
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "α-Syn aggregation" in MCE Product Catalog:
9
9 Publications Verification
Synonyms: 6PPD-Quinone
Category:
Alkaloids Quinones Other Alkaloids Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields
Target:
5
5 Cited Publications
Cat. No.: HY-N0901A
CAS No.: 17391-18-3
Category:
Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Rubiaceae Plants Disease Research Fields Cancer Indole Alkaloids
Target:
Synonyms: Anle138b
Target:
Research Areas:
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
Synonyms: UCB0599; (R)-NPT200-11
Target:
Research Areas:
Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
Target:
Research Areas:
MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research .
Cat. No.: HY-157700
CAS No.: 97802-53-4
Synonyms: C16(Plasm) LPC; Lysophosphatidylcholine 16:0p/0:0
Target:
Research Areas:
Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research .
Cat. No.: HY-163830
Synonyms: DAD9
Target:
Research Areas:
Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease .
Target:
Research Areas:
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .
Cat. No.: HY-170381
Target:
Research Areas:
α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y .
Cat. No.: HY-139830
CAS No.: 2858696-72-5
Target:
Research Areas:
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
Cat. No.: HY-16468A
CAS No.: 1309370-82-8
Synonyms: ENT 01; MSI-1256 phosphate
Target:
Research Areas:
Squalamine phosphate (Compound ENT-01) is an orally active neuroprotective agent. Squalamine phosphate can displace α-Syn that is bound electrostatically to nerve cell membranes and prevent aggregation of α-Syn. Squalamine phosphate can be used for the research of neurological disease, such as Parkinson’s disease .
Cat. No.: HY-N10306
CAS No.: 3034046-94-8
Target:
Cat. No.: HY-170553
Target:
Research Areas:
ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .
Cat. No.: HY-163739
CAS No.: 951131-13-8
Target:
Research Areas:
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .
Cat. No.: HY-163519
Target:
Research Areas:
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .
Cat. No.: HY-149509
CAS No.: 1510825-03-2
Target:
Research Areas:
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
Cat. No.: HY-157806
Target:
Research Areas:
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .
Cat. No.: HY-147666
CAS No.: 2489813-08-1
Target:
Research Areas:
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 0.98 μM and inhibition ratio at 30 μM of 91.2% .
Cat. No.: HY-147667
CAS No.: 2489813-11-6
Target:
Research Areas:
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3% .
Cat. No.: HY-147668
CAS No.: 2489813-02-5
Target:
Research Areas:
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.70 μM and inhibition ratio at 30 μM of 94.4% .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
